1[1]Compo E,Merion MJ,Liotta L, et al. Distribution of the 72-kd type Ⅳ collagenase in nonneoplastic thyroid tissue[J].Hum Pathol, 1992, 23(12):1395-1401.
2[2]Vasconcelos A, Medeiros R, Veiga I, et al. Analysis of estrogen receptor polymorphism in codon 325 by PCR-SSCP in breast cancer:association with lymph node metastasis[J]. Breast J, 2002,8 (4): 226-229.
3[3]Lavezzi AM, Ottaviani G, De Ruberto F, et al. Prognostic significance of different biomarkers (DNA content,PCNA, karyotype)in colorectal adenomas[J]. Anticancer Res, 2002,22 ( 4 ): 2077 -2081.
4[4]Shurbaji MS, Brooks SK, Thurmond TS, et al. Proliferating cell nuclear antigen immunoreactivity in cervical intraepithelial neoplasia and benign cervical epithelium [J]. Am J Clin Pathol, 1993,100:22-26.
5Steeg PS, Bevilacqua G, Kopper L, et al. Evidence for a novel gene assiociated with low tumor metastatic potential[J]. J Nail Cancer Inst,1988,80(3) :200-204.
6Mao H,Liu H,Fu X,et al. Loss of nm23 expression predicts distal metastases and poorer survival for breast cancer[J]. Int J Oncol,2001,18(3) : 587-591.
7Nakopoulou LL, Tsitsimelis D, Lazaris AC, et al. nm23, c-erbB-2, and progesterone receptor expression in invasive breast cancer: correlation with clinicopathologic parameters[J]. Cancer Detect Prey, 1999, 23(4) :297.
8Degeorges A, Roquaaomm A, Extra JM, et al. Is p53 a protein that prediets the response to chemotherapy in node negative breast cancer[J]? Breast Cancer Res Treat, 1998,47(1) : 47-55.
9Piccorf MJ, Di Leo A, Hamilton A. HER2: a predictive factor ready to use in he daffy management of breast patients[J]? Eur J Cancer 2000,36:1735-1761.
10Berns EMJJ, Foekns JA, Van IL, et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment[J].Gene, 1995,159(8) : 11-18.
